Form 8-K - Current report:
SEC Accession No. 0000950170-24-129402
Filing Date
2024-11-20
Accepted
2024-11-20 17:08:36
Documents
20
Period of Report
2024-11-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lctx-20241119.htm   iXBRL 8-K 63447
2 EX-4.1 lctx-ex4_1.htm EX-4.1 151485
3 EX-4.2 lctx-ex4_2.htm EX-4.2 139613
4 EX-4.3 lctx-ex4_3.htm EX-4.3 151726
5 EX-5.1 lctx-ex5_1.htm EX-5.1 33332
6 EX-10.1 lctx-ex10_1.htm EX-10.1 312887
7 EX-10.2 lctx-ex10_2.htm EX-10.2 311744
8 EX-99.1 lctx-ex99_1.htm EX-99.1 23230
9 GRAPHIC img133474293_0.jpg GRAPHIC 8188
10 GRAPHIC img176613450_0.jpg GRAPHIC 40918
  Complete submission text file 0000950170-24-129402.txt   1573772

Data Files

Seq Description Document Type Size
11 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lctx-20241119.xsd EX-101.SCH 23883
22 EXTRACTED XBRL INSTANCE DOCUMENT lctx-20241119_htm.xml XML 4516
Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Filer) CIK: 0000876343 (see all company filings)

EIN.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12830 | Film No.: 241481274
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)